Tolcher, Anthony W. http://orcid.org/0000-0002-6322-9721
Kurzrock, Razelle
Valero, Vincente
Gonzalez, Rene
Heist, Rebecca S.
Tan, Antoinette R.
Means-Powell, Julie
Werner, Theresa L.
Becerra, Carlos
Wang, Chenxi
Leonowens, Cathrine
Kalyana-Sundaram, Shanker
Kleha, Joseph F.
Gauvin, Jennifer
D’Amelio, Anthony M. Jr.
Ellis, Catherine
Ibrahim, Nageatte
Yan, Li
Article History
Received: 5 September 2019
Accepted: 31 January 2020
First Online: 15 February 2020
Compliance with ethical standards
:
: A. W. T. has received fees for consulting and board memberships, as well as research funding (paid to NEXT Oncology) from AbbVie, ADC Therapeutics, Adagene, Agenus, Aminex, AroBioTX, Arrys, Asana, Ascentage, Aximmune, Bayer, Biolnvent, Birdie, Boston Bio, CStone, Deciphera, EMD Serono, Forbius, GSK, HBM Partners, Ignyta, Inhibrx, Immunome, Immunomet, Innate, Jazz Pharmaceuticals, Kiromet, Mekanistic, Mersana, Nanobiotix, NatureWise, NBE Therapeutics, NextCure, Nitto Biopharma, Nuvalent, Pelican, Pfizer, Pierre Fabre, Pieris, Ridgeway, Scitemex, Sesen Bio, Seattle Genetics, Sunshine Guojian, Symphogen, Syndax, Syneos, Tizone, and Zymeworks. R. K. has received research funding from Boehringer Ingelheim, DeBiopharm, Foundation Medicine, Genentech, Grifols, Guardant Health, Incyte, Konica Minolta, Merck Serono, OmniSeq, Pfizer, and Sequenom; has consulting or advisory role in Actuate Therapeutics, Gaido, LOXO, NeoMed, Pfizer, Roche, Soluventis, and X-Biotech; has received speaker fees from Roche; is a board member of CureMatch, Inc.; and has stock and other equity interests in CureMatch, Inc., IDbyDNA, and Soluventis. V. V. received grant and honorarium from Novartis. R. G. received research funding from Novartis, GSK and grant and personal fees from Array, Bristol-Myers Squibb, Merck, and Roche/Genentech. R. S. H. received consulting honoraria from Boehringer Ingelheim, Novartis, Tarveda, Apollomics and received research funding (to his institution) from Daiichi Sankyo, Agios, Novartis, Corvus, Mirati, Millennium, Genentech Roche, AbbVie, Exelixis, Celgene, and Incyte. A. R. T. received research funding from GSK. C. W. and S. K-S. are employees of GSK. C. L. and L. Y. were former employees of GSK. J. F. K. was an employee of Novartis. J. G. and A. M. D. Jr. are employees of Novartis Pharmaceuticals and have stock ownership in Novartis and GSK. C. E. is an employee and stock owner of GSK. N. I. was an employee of GSK and currently is an employee of Merck. All remaining authors have declared no conflicts of interest. All authors received assistance with manuscript preparation from ArticulateScience, LLC.